布基纳法索和马里两地 intense 季节性疟疾传播区 SMC 效果评估:家庭随机安慰剂对照试验二次分析
该研究基于布基纳法索 Houndé 和马里 Bougouni 的家庭随机安慰剂对照试验,评估季节性疟疾化学预防(SMC)在約 10,000 名 3–59 月龄儿童中的保护效果。结果显示,尽管 SMC 覆盖率和依从性高,疟疾住院或死亡及无并发症疟疾发病率仍较高,且发病高峰在每年 7 月 SMC 开始前。过去 28 天内接受 SMC 对比超过 35 天前,对疟疾住院和死亡的保护效力为 87.4%,对无并发症疟疾为 78.3%。
要点
- SMC 对疟疾住院和死亡的保护效力为 87.4%(95%CI 79.6–92.2)。
- SMC 对无并发症疟疾的保护效力为 78.3%(95%CI 76.8–79.6)。
- 研究区疟疾负担仍高,发病高峰在 7 月,早于 8 月 SMC 开始。
核心结论
- 尽管 SMC 提供高水平保护,两个研究地区的疟疾负担仍然很高,需继续支持 SMC 项目。
- 研究地区及类似流行病学设置需要第五次月度 SMC 疗程以充分覆盖整个传播季节。
研究设计与样本
- 基于大型家庭随机安慰剂对照试验的二次分析,在布基纳法索 Houndé 和马里 Bougouni 开展。
- 2014 年 7 月将 19,578 名 3–59 月龄儿童按家庭随机分组,每年 8–11 月直接观察治疗下给予 4 次月度 SMC 加阿奇霉素或安慰剂。
- 分析聚焦 SMC 加安慰剂组每年约 10,000 名儿童(每国约 5,000 名)。
主要发现
- 疟疾住院或死亡总发病率为 12.5 例/1000 人年(95%CI 11.2–14.1),无并发症临床疟疾为 871.1 例/1000 人年(95%CI 852.3–890.6)。
- 过去 28 天内 SMC 对比超过 35 天前,疟疾住院和死亡的发病率比为 0.13(95%CI 0.08–0.20,P<0.001)。
- 无并发症疟疾的发病率比为 0.21(95%CI 0.20–0.23,P<0.001)。
- 错过调查前 SMC 疗程的儿童,雨季周调查和传播季末疟原虫血症患病率更高,最小患病率比为 2.98(95%CI 1.95–4.54,P<0.001)。
- SMC 实施 3 年后,无症状疟疾儿童中 SP+AQ 方案第 28 天 PCR 未校正充分临床和寄生虫学应答率在布基纳法索为 98.3%(95%CI 88.6–99.8),马里为 96.1%(95%CI 91.5–98.2)。
关键数值与推荐
- SMC 对疟疾住院和死亡的保护效力为 87.4%(95%CI 79.6–92.2)。
- SMC 对无并发症疟疾的保护效力为 78.3%(95%CI 76.8–79.6)。
- 研究期间 SP 和 AQ 耐药分子标志物频率在研究儿童或学龄儿童中未显著增加。
临床怎么用
- 在类似流行病学设置中,应考虑增加第五次月度 SMC 疗程以覆盖整个传播季节。
- 需继续支持 SMC 项目以维持高保护水平。
局限性
- 快速诊断试验可能过度诊断无并发症疟疾。
- 与月度 SMC 方案依从性相关的因素可能带来残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Seasonal malaria chemoprevention (SMC) is now widely deployed in the Sahel, including several countries that are major contributors to the global burden of malaria. Consequently, it is important to understand whether SMC continues to provide a high level of protection and how SMC might be improved. SMC was evaluated using data from a large, household-randomised trial in Houndé, Burkina Faso and Bougouni, Mali. METHODS AND FINDINGS: The parent trial evaluated monthly SMC plus either azithromycin (AZ) or placebo, administered as directly observed therapy 4 times per year between August and November (2014-2016). In July 2014, 19,578 children aged 3-59 months were randomised by household to study group. Children who remained within the age range 3-59 months in August each year, plus children born into study households or who moved into the study area, received study drugs in 2015 and 2016. These analyses focus on the approximately 10,000 children (5,000 per country) under observation each year in the SMC plus placebo group. Despite high coverage and high adherence to SMC, the incidence of hospitalisations or deaths due to malaria and uncomplicated clinical malaria remained high in the study areas (overall incidence rates 12.5 [95% confidence interval (CI): 11.2, 14.1] and 871.1 [95% CI: 852.3, 890.6] cases per 1,000 person-years, respectively) and peaked in July each year, before SMC delivery began in August. The incidence rate ratio comparing SMC within the past 28 days with SMC more than 35 days ago-adjusted for age, country, and household clustering-was 0.13 (95% CI: 0.08, 0.20), P < 0.001 for malaria hospitalisations and deaths from malaria and 0.21 (95% CI 0.20, 0.23), P < 0.001 for uncomplicated malaria, indicating protective efficacy of 87.4% (95% CI: 79.6%, 92.2%) and 78.3% (95% CI: 76.8%, 79.6%), respectively. The prevalence of malaria parasitaemia at weekly surveys during the rainy season and at the end of the transmission season was several times higher in children who missed the SMC course preceding the survey contact, and the smallest prevalence ratio observed was 2.98 (95% CI: 1.95, 4.54), P < 0.001. The frequency of molecular markers of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) resistance did not increase markedly over the study period either amongst study children or amongst school-age children resident in the study areas. After 3 years of SMC deployment, the day 28 PCR-unadjusted adequate clinical and parasitological response rate of the SP + AQ regimen in children with asymptomatic malaria was 98.3% (95% CI: 88.6%, 99.8%) in Burkina Faso and 96.1% (95% CI: 91.5%, 98.2%) in Mali. Key limitations of this study are the potential overdiagnosis of uncomplicated malaria by rapid diagnostic tests and the potential for residual confounding from factors related to adherence to the monthly SMC schedule. CONCLUSION: Despite strong evidence that SMC is providing a high level of protection, the burden of malaria remains substantial in the 2 study areas. These results emphasise the need for continuing support of SMC programmes. A fifth monthly SMC course is needed to adequately cover the whole transmission season in the study areas and in settings with similar epidemiology. TRIAL REGISTRATION: The AZ-SMC trial in which these data were collected was registered at clinicaltrials.gov: NCT02211729.
引用
- Cairns ME, Sagara I, Zongo I, et al. Evaluation of seasonal malaria chemoprevention in two areas of intense seasonal malaria transmission: Secondary analysis of a household-randomised, placebo-controlled trial in Houndé District, Burkina Faso and Bougouni District, Mali. PLoS Med. 2020. PMID: 32822362. doi:10.1371/journal.pmed.1003214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。